1. Introduction {#sec0005}
===============

Coronaviruses (CoVs) are a large family of virus phenotypically and genotypically diverse belonging to the subfamily Orthocoronavirinae of the Coronaviridae family (order Nidovirales) ([@bib0040]). Although enzootic infections in birds and mammals are more usual, coronaviruses have been infecting humans as well in the last decades ([@bib0575]). The lethality of coronaviruses infection after crossing this species barrier is high, as demonstrated by the outbreak of severe acute respiratory syndrome (SARS) in 2002, followed by the Middle East respiratory syndrome (MERS) in 2012, originated by SARS‐CoV and MERS‐CoV, respectively ([@bib0145]; [@bib0850]). In December 2019, cases of pneumonia of unknown cause were firstly reported in Wuhan, Hubei Province, China, which were later confirmed to be caused by the novel coronavirus SARS-CoV-2 ([@bib0405]; [@bib0840]). Evidence of human‐to‐human transmission was confirmed via respiratory droplets or direct contact with the infected patients, and this new coronavirus infection was further named COVID-19 ([@bib0405]; [@bib0445]) and recognized by World Health Organization as an ongoing coronavirus pandemic in march 11, 2020. The virus has spread quickly to almost all countries and already infected millions of people and caused hundreds of thousands of deaths. COVID-19 symptoms usually appear 2--14 days after viral exposure and usually include fever, cough, shortness of breath and pneumonia, among others. Severe cases often display respiratory, hepatic, gastrointestinal and neurological complications that ultimately culminate in hospitalization and death, with some differences in lethality when compared with the previous SARS‐CoV/MERS‐CoV infections ([@bib0500]; [@bib0610]). Currently, there is no registered treatment or vaccine for SARS-CoV-2 infection and new solutions to halt or slow down virus replication and dissemination are an urgent need. Apart from the efforts to develop a vaccine, several therapeutic options are currently being evaluated, including drug repurposing of distinct anti-viral, immunomodulatory or anti-inflammatory agents, as well as drugs targeting a functional receptor for SARS-CoV-2 entry into human cells, the angiotensin converting enzyme 2 (ACE2) ([@bib0440]; [@bib0555]; [@bib0590]; [@bib0800]).

ACE2, a homologue of ACE, has been described as a negative regulator of the Renin-Angiotensin System (RAS), alleviating the deleterious actions mediated by Ang II signaling through Ang II receptor type 1 (AT1R) ([@bib0390]). This role is of extreme relevance in pathological conditions associated with RAS overactivation, including those related with cardiovascular, renal and pulmonary systems ([@bib0140]). Besides, ACE2 also displays non-RAS-related roles linked with neutral amino acids transport and gut homeostasis; conditions of impaired ACE2 expression or function are potentially promoters of intestinal dysbiosis ([@bib0525]). This is aligned with the gastrointestinal (GI) symptoms, such as nausea and diarrhea, that have been reported in COVID-19 patients, suggesting an impact on gastrointestinal-enteric system ([@bib0370]).

Gut microflora plays major functions for the host homeostasis, including metabolic effects, structural protection against pathobionts (namely preserving the intestinal barrier composition and permeability), as well as "education" of host immunity ([@bib0395]; [@bib0580]). Typically, the intestinal barrier prevents the translocation of harmful substances and microbes from the lumen to the bloodstream; however, deregulation of the intestinal milieu promotes gut dysbiosis, including increased gut barrier permeability and the passage of microbiota-derived inflammatory components that activate the innate immune system and promote a state of endotoxemia/inflammation ([@bib0175]). Gut microbiota (GM) composition and diversity is affected by many factors, including by ageing. An apparent age-related gut microbiota imbalance has been underscored in the last years, featured by an altered microbial diversity, a lower abundance of probiotic strains (e.g. *Bifidobacteria*) and a reduced number of species producing butyrate, a short chain fatty acid (SCFA) that plays important metabolic functions and has a major role in maintaining the integrity of intestinal epithelium ([@bib0465]). Accordingly, mounting evidences outline a key role for gut dysbiosis in age-related cardiovascular, metabolic and renal disorders ([@bib0005]; [@bib0460]; [@bib0480]; [@bib0550]). Interestingly, poor outcomes of COVID-19 infection have been observed in elderly patients, particularly those with pre-existing cardiovascular, metabolic and renal disorders, in whom the disease severity and the mortality rate are considerably higher ([@bib0160]; [@bib0435]; [@bib0490]; [@bib0545]; [@bib0605]; [@bib0610]; [@bib0660]; [@bib0715]; [@bib0835]).

This review highlights the evidence pointing the ACE2 imbalance as a key player for the poor outcomes in the COVID-19 patients with those age-related preexisting comorbidities and addresses a possible role for gut microbiota dysbiosis in this interplay. The article culminates with the therapeutics opportunities based on the modulation of these pathways.

2. Trilogy of ACE2 roles: a unifying perspective {#sec0010}
================================================

2.1. ACE2 as a SARS-CoV-2 receptor responsible for COVID-19 {#sec0015}
-----------------------------------------------------------

ACE2, an ubiquituous type I membrane-anchored glycoprotein enclosing 805 amino acids, displays monocarboxypeptidase catalytic activity with various substrates already identified. Full-length ACE2 consists of an N- terminal peptidase domain (PD) and a C-terminal collectrin-like domain (CLD) that ends with a single transmembrane helix and an intracellular tail ([@bib0245]; [@bib0760]). Furthermore, it is susceptible to cleavage between amino acids 716 and 741, with subsequent release of the catalytic active ectodomain, mainly due to TNF-α-converting enzyme (TACE, also known as ADAM-17).

ACE2 is a counter-regulator of ACE activity mainly by converting angiotensin I (Ang I) into a nonapeptide (Ang 1--9) and angiotensin II (Ang II) into a vasoprotective heptapeptide (Ang 1--7) ([@bib0515]). Notably, TACE overstimulation may culminate in RAS overactivation and both events have been reported in some cardiovascular inflammatory diseases, namely in heart failure and coronary artery disease ([@bib0225]; [@bib0600]). Recently, ACE2 has garnered great interest on the basis of their peptidase-independent actions as a functional receptor of SARS coronaviruses, including the new SARS-CoV-2.

SARS-CoV-2 is a single-stranded RNA-enveloped virus provided with crown-like spike (S) glycoproteins on the outer surface that give the coronavirus its name. S glycoprotein is present as a trimer and displays two functional subunits: while S1 subunit encloses the receptor-binding domain (RBD) and is responsible for the recognition to the host ACE2 receptor, S2 subunit comprises the fusion machinery that mediates virus fusion in transmitting host cells ([@bib0030]). ACE2-spike interaction leads to endocytosis of virus particles and subsequent release of genomic material through internalization with ACE2.

Analogous to previously identified SARS-CoV, SARS-CoV-2 spikes need to be proteolytically activated for membrane fusion via irreversible conformational changes ([@bib0685]). Host proteases for S-protein priming, receptor binding and cell entry include type 2 transmembrane protease serine 2 (TMPRSS2) as well as cathepsin L, cathepsin B, trypsin, factor X, furin, and elastase ([@bib0280]; [@bib0585]; [@bib0740]). Hence, a concerted action of receptor binding and S-protein proteolytic processing is required for SARS-CoV-2 entry into susceptible cells and great efforts have been made to fully disclose the underlying mechanisms towards effective pharmacological modulation. Notably, S-protein preactivation also comprises C-terminal ACE2 cleavage to enhance receptor-mediated endocytosis and S-protein-driven viral entry. Thus, the abrogation of membranar ACE2-mediated cytoprotection is a first event of SARS-CoV-2 infection.

Once inside the cell, SARS-CoV-2 activates the mechanisms of replication, namely by synthesizing viral polyproteins encoding for the replicase-transcriptase complex, followed by RNA synthesis by its RNA-dependent RNA polymerase, culminating in the synthesis of structural biomolecules required for virus assembly and subsequent release ([@bib0120]; [@bib0585]; [@bib0740]).

2.2. ACE2 as a RAS counterbalance in cardiovascular, renal, respiratory and GI systems {#sec0020}
--------------------------------------------------------------------------------------

The RAS plays a relevant role in different body' organs (such as the heart, kidney, and lung) and systems (namely circulatory and renal), through both local actions and systemic effects, including the regulation of blood pressure and electrolyte and liquid homeostasis ([@bib0410]). RAS is a highly regulated system whose main functions are accomplished by several bioactive peptides originated from a cascade of proteases. Briefly, angiotensinogen is mainly produced and secreted by the liver and cleaved by renin (produced by the juxtaglomerular apparatus in the kidney) in the Ang I. This decapeptide can be then cleaved by ACE in the octapeptide Ang II, the main bioactive component of RAS, which exerts a variety of actions by linking with G-protein-coupled receptors Ang II receptor type 1 and type 2 (AT1R and AT2R, respectively). While Ang II signaling through AT1R is associated with vasoconstrictive, pro-hypertensive, pro-oxidant, pro-inflammatory, and pro-fibrotic effects on tissue, AT2R activation has opposing effects mediated by a vasodilatory cascade with participation of NO, cGMP, or bradykinin ([@bib0035]). Over the last twenty years since its discovery, ACE2 has changed the paradigm of RAS in many aspects. ACE2 gene is expressed in many human tissues, including in the heart, kidney, liver, upper airways, lungs, gut, among others. ACE2 catalyzes the conversion of Ang II into Ang 1--7, a biologically active peptide that activates Mas receptor (MasR), its endogenous orphan receptor, promoting many opposite effects to those attributed to Ang II ([@bib0390]; [@bib0560]). Thus, the ACE2/Ang 1--7/MasR axis over time was established as the physiological counter-regulator of Ang II in the RAS ([@bib0520]; [@bib0830]). Apart from signaling through the MasR, Ang 1−7 can also act as an AT1R antagonist, further counteracting the ACE/Ang II/AT1R axis ([@bib0215]).

The role of this axis is of special relevance in conditions associated with RAS overactivation, which includes age-related cardiac, vascular, renal and respiratory diseases, among others ([@bib0140]; [@bib0320]; [@bib0390]). ACE2-protective effects can be ascribed by a combination of i) downregulation of ACE action due to degradation of its substrate (Ang I) to Ang 1--9, ii) reduction of Ang II-detrimental effects by promoting its degradation and iii) potentiation of cardioprotective actions of Ang 1--7 via MasR or by antagonizing AT1R. Beneficial effect of ACE2/Ang 1--7 have been described in several animal models, namely associated with anti-hypertensive properties, improvement of myocardial performance, cardiac remodeling, and increased survival in heart failure, ischemia/reperfusion injury and myocardial infarction ([@bib0695]; [@bib0830]).

Regarding the kidney, ACE2 is expressed in the brush border of the proximal tubule epithelial cells, where it contributes to regulate blood pressure and salt and fluid homeostasis ([@bib0720]). Although ACE2 has been mostly associated with renoprotective effects in some animal models of nephropathy, including in diabetic kidney injury, namely by the reduction of Ang II levels and its pro-hypertensive and vasoconstrictor actions ([@bib0050]; [@bib0730]), the renal injury induced by ACE2 and Ang 1−7 was paradoxically reported under other experimental conditions, including in diabetic nephropathy, deserving further clarification ([@bib0845]).

In the lung, ACE2 seems to ameliorate pulmonary hypertension and pulmonary fibrosis ([@bib0185]; [@bib0430]), in opposition to the effects reported for increased Ang II levels ([@bib0475]). In addition, RAS activation has been associated with acute lung injury and acute respiratory distress syndrome ([@bib0470]). Interestingly, recombinant ACE2 treatment was able to overcome the severe acute lung injury observed in ACE2 knock-out mice ([@bib0315]), suggesting a putative protection against lung injury.

Although the GI tract is one of the major players in fluid and electrolyte intake and excretion, the role of RAS in the GI system only recently was well characterized. There are now consistent preclinical evidences of the presence of all RAS components (including ACE2) throughout the GI tract required for autonomous regulation, supporting their involvement in GI physiology and pathophysiology ([@bib0210]; [@bib0625]). In fact, local RAS is involved in the regulation of glucose, amino acid, fluid and electrolyte absorption and secretion, blood flow, motility and inflammation, and could be a promising target for GI disorders, such as inflammatory bowel disease, among others ([@bib0210]).

Overall, suppression of ACE2-protective roles due to ACE2 depletion upon SARS-CoV-2 infection is very likely to uphold the poor outcomes observed in elderly COVID-19 positive patients, especially in those with pre-existing cardiovascular, metabolic and renal diseases.

2.3. ACE2 as a regulator of intestinal amino acid transport that impacts gut microbiota {#sec0025}
---------------------------------------------------------------------------------------

It is now acknowledged that ACE2 also displays important non-RAS-related roles. A non-catalytic, yet functional role for ACE2 was first hypothesized upon the observation of a constitutive ACE2 expression within the luminal surface of differentiated small intestinal epithelial cells and colonic crypt cells ([@bib0250]). ACE2 shares great homology (around 50 %) with collectrin, a type 1 transmembrane protein that regulates the transporter of neutral amino acids in the kidney ([@bib0805]). Further studies confirmed that ACE2 functions as the chaperone for membrane trafficking of the aminoacid transporter B°AT1, which mediates the uptake of neutral amino acids into intestinal cells in a sodium-dependent manner, even in the absence of collectrin ([@bib0090]; [@bib0380]). Studies with ACE2-KO animals showed reduced serum levels of neutral amino acids, namely tryptophan (Trp), together with downregulated expression of small intestinal antimicrobial peptides (AMPs) and impaired gut microbial composition, which was reestablished by Trp supplementation ([@bib0260]). This was the first work linking the ACE2-mediated amino acid transport to gut microbial ecology. It is currently proposed that mTOR activation, trough nutrient sensing and/or through the Trp-nicotinamide pathway, regulates AMPs expression and subsequent gut microbiota composition ([@bib0260]; [@bib0525]). Mounting evidences suggested beneficial effects of ACE2 on several cardiovascular conditions involving the use of AMPs (such as LL-37, defensins or PR-39) and/or impact on gut microbiota ([@bib0310]; [@bib0375]; [@bib0820]). The association between changes on Trp transport and intestinal microbiota composition and diversity has been also supported by both preclinical and clinical studies of malnutrition associated with Kwashiorkor. In fact, children from rural regions of Malawi, with a low protein diet, were unable to develop microbiota gene diversity in the adulthood ([@bib0615]). Furthermore, transplantation of their feces to gnotobiotic mice confirmed the association between malnutrition and intestinal disease, which was reinforced by studies using mice feed with protein or Trp-free diet that developed gut microbiota dysbiosis and colitis ([@bib0260]).

3. Gut microbiota roles linking immunity, infection and cardiometabolic disease {#sec0030}
===============================================================================

3.1. Gut microbiota, host immune system and coronaviruses infection {#sec0035}
-------------------------------------------------------------------

After a virus invades the host, it is usually first recognized by antigen presenting cells (APCs) within host innate immune system. Several pattern recognition receptors (PRRs) located in distinct compartments of the host cells recognize viral structural components and/or intermediate products (e.g. nucleic acids, glycoproteins, dsRNA), collectively termed pathogen-associated molecular patterns (PAMPs), thereby triggering the production of immune system cell effectors ([@bib0030]). Toll-like receptors (TLRs), nucleotide binding oligomerization domain (NOD)-like receptors and/or cytoplasmatic RIG-like receptors (RLR) are some examples of PRRs expressed in innate immune cells (e.g. plasmacytoid dendritic cells) who serve as the primary viral sensors for the innate antiviral effector programs, such as the canonical type I interferon (Type I IFN) response. Downstream signaling cascades foster viral antigens phagocytosis by host macrophages and play a major role in orchestrating the development of the adaptive immune response to infection ([@bib0425]; [@bib0780]). In fact, cytokine microenvironment generated by APCs modulates Th1 type adaptive immunity. For instance, CD8^+^ T cells priming and activation by APCs accomplish virus-infected cells abrogation through distinct effector molecules (e.g. granzyme B, perforin). In addition, CD4^+^ T cells evoke a cytokine-mediated Th1-polarized cellular program in other immune cells (e.g. macrophages) and regulate regulate humoral immune responses towards virus-specific antibodies production. In short, a complex coordination between innate immune cells and lymphocytes is required to achieve a balanced immune response able to control systemic viral infection ([@bib0725]).

The mechanisms of how CoVs' infection modulate host immune responses appear to follow similar traits ([@bib0530]). Previous studies, especially on SARS-CoV and MERS-CoV infections, have shown an overreaction of the immune system and subsequent "cytokine storm", featured by an exacerbated systemic inflammatory response and the massive release of TNFα, IL-1β, IL-2, IL-6, IFNα, IFNβ, IFNγ, and MCP-1 ([@bib0100]). These findings are in line with the high-levels of pro-inflammatory cytokines (e.g. IL-1, IL-2, IL-7, G-CSF, IP-10, MCP-1, MIP-1A and TNFα) observed in COVID-19 severe cases ([@bib0300]). Hence, the so-called "cytokine storm" is very likely to contribute to the poor outcomes and mortality rate of COVID-19 worldwide, as found in SASR-CoV and MERS-CoV infections. Strikingly, these conditions are often caused by multi-organ failure mainly in elderly patients with chronic comorbidities displaying a self-sustaining loop of immunosenescence and inflammaging ([@bib0190]; [@bib0205]). Age-related cardiovascular, metabolic and renal diseases fit this unhelpful scenario (see Section [3](#sec0030){ref-type="sec"}). Briefly, adaptive changes in the immune system as a consequence of aging (immunosenescence) often parallels a scenario of low-grade inflammation (inflammaging) featured by high concentrations of acute phase reactants and pro-inflammatory cytokines ([@bib0200], [@bib0205]). Yet, in a given environment, deregulated immune responses to external factors may become particularly relevant, namely in the case of older individuals coping with infected pathogens ([@bib0595]). Notably, this mutually maintained state between immunosenescence and inflammaging that ensues in the elderly is strongly modulated by changes in GM ([@bib0015]; [@bib0060], [@bib0065]; [@bib0595]).

Major advances in our understanding of the mutual interplay between host immune system and gut microbiota have been achieved in the last decade ([@bib0055]). It is now well established that commensal microbiota (GI tract, oral, respiratory, genitourinary, and dermal) plays a central role in assembling mammalian immune effectors for an optimal antiviral immune response ([@bib0130]). Increasing evidences highlight that commensal gut microbiota-derived ligands, collectively termed microbe-associated molecular patterns (MAMPs), are able to engage PRRs towards a balanced tunning of pro- and anti-inflammatory responses arising from innate and adaptive host immunity ([@bib0135]). Thus, an interconnected immune program with differential immunological reactions for pathogenic or commensal microorganisms-derived signals occurs through PRRs expressing cells, based on the ligand (PAMPs or MAMPs), cell type and/or receptors involved ([@bib0350]).

Although the underlying molecular pathways remain to be well established, there are distinct mechanisms through which gut microbiota shapes local and distal immune components during systemic viral infection. While viral antigens are recognized by endosomal and cytoplasmic PRRs, commensal gut microbiota helps to set a homeostatic type I IFN-dependent immune response at distal non-GI tract sites, a central component for virus control ([@bib0455]; [@bib0650]). A second important topic relies on gut microbiota ability to regulate NF-kB and inflammasome-dependent release of pro-inflammatory cytokines (e.g. TNF-α, IL-6, IL-1β, and lL-18) which are crucial for the distal recruitment of immunocompetent cells (e.g. monocytes, granulocytes, dendritic cells) that circumscribe viral replication ([@bib0110]). A tight coordination between adaptive immune responses and gut microbiota is also steadily highlighted. For instance, secondary lymphoid tissues development at distal non-GI tract sites and differentiation/maturation of T and B cells (including virus-specific effectors CD4^+^ and CD8^+^ T cells) are extensively shaped by commensal gut microbiota ([@bib0110]). Moreover, gut microbial-derived metabolites are very likely to modulate systemic viral infection outcomes. Accordingly, a microbial-derived metabolite produced by the human-associated commensal gut bacteria Clostridium orbiscendens -- desaminotyrosine -- was able to protect mice from lethal Influenza Virus infection, presumably due to the vigorous priming and amplification of type I IFN-dependent antiviral immune response ([@bib0630]). Similarly, the impact of intestinal (and lung) commensal microorganisms on the fine tuning of host immunity upon distinct respiratory viruses infection is also well-known ([@bib0230]; [@bib0345]; [@bib0705]). Notably, age-related alterations in gut microbiota composition and function deeply impairs local (gut) and distal immunity. For instance, it is known that the systemic priming of inflammasomes (a mechanism closely regulated by gut microbiota) increases with age ([@bib0175]). Hence, the threshold for full inflammasome activation by a "second hit" (for instance, a viral infection) might be reached easier with ageing, analogous to what has been reported in vascular and renal patients ([@bib0620]; [@bib0735]). Taking into account that elderly patients often carry a silent "inflammaging" condition and an immunonescence phenotype, age-related gut dysbiosis may additionally support an imbalanced immune response and overreactive inflammatory phenotype when a new challenge is faced, as is the case of SARS-CoV-2 infection. By looking at the previous outbreak of SARS and MERS, the mechanisms of how SARS-CoV and MERS-CoV evade host immunity greatly depend on the inhibition of the canonical type I IFN antiviral response ([@bib0530]). An imbalanced immune response towards an excessive inflammatory phenotype ("cytokine storm") has harmful consequences to lungs and vital organ systems and seems to correlate with the poor outcomes in CoVs infections, including in elderly COVID-19 patients. Accordingly, new biomarkers directed towards a deep understanding of how age-related mechanisms modulate respiratory SARS-CoV-2 infectious disease may have long-term gain in COVID-19 pandemic, as recently highlighted ([@bib0195]).

SARS-CoV-2, as a member of the Betacoronavirus genus, potentially shares with SARS-CoV and MERS-CoV some immune evasion mechanisms and host immunological priming. As scrutinized beyond, a healthy gut microbiota may be a cardinal vantage for host immune system to thwart viral infections such as coronaviruses, namely on the basis of its impact on important host immune responses recruited upon CoVs infections. Noteworthy, GM dysbiosis was observed in hospitalized COVID-19 patients, featured by an imbalance of intestinal microflora diversity with decrease levels of probiotic bacteria (e.g. Lactobacillus and Bifidobacterium) ([@bib0755]), a higher relative abundance of opportunistic pathogens (e.g. Streptococcus, Rothia, Actinomyces) and a lower relative abundance of beneficial symbionts ([@bib0235]; [@bib0855]). Notably, these shifts in GM composition persisted after respiratory symptoms resolution and were correlated with COVID-19 severity ([@bib0855]). Altogether, these emerging observations pave the way for incoming studies centered on gut microbiota and mammalian host immune relationships upon SARS-CoV-2 infection which may bring new faithfull insights for COVID-19 management ([@bib0270]).

3.2. Gut microbiota dysbiosis and cardiovascular, metabolic and renal diseases {#sec0040}
------------------------------------------------------------------------------

Mounting evidences coming from preclinical and clinical research strongly suggest that dysbiosis of intestinal microflora is involved in age-related cardiovascular, metabolic and renal diseases ([@bib0485]; [@bib0505]). Several studies showed a reduced diversity, resilience and impaired prevalence of Firmicutes to Bacterioidetes ratio (a marker of dysbiosis) in patients with obesity or type 2 diabetes mellitus ([@bib0080]; [@bib0415]). Briefly, conditions that promote an impaired intestinal microbiota, such as hypercaloric diets, can cause i) deregulation of gut barrier integrity due to reduced tight junctions density and subsequent ii) translocation of bacteria fragments \[namely lipopolysaccharide (LPS) and peptidoglycan (PG)\] from the gut lumen to the bloodstream leading to endotoxemia, also referred as a low-grade inflammation state ([@bib0070]; [@bib0220]; [@bib0485]). These MAMPs, through TLRs signaling, namely TLR4, cause a pro-inflammatory and immune response, thereby affecting glucose and insulin metabolism and/or signaling ([@bib0070]). This is aggravated by impaired production of SCFAs by symbiotic bacteria and reduced release of intestinal peptides such as peptide YY (PYY) and glucagon-like peptide-1 (GLP-1), collectively promoting inflammation and insulin insensitivity in peripheral tissues as well as central satiety control impairment ([@bib0075]). Concurrently, signals coming from the dysbiotic gut microbiota modulate immunometabolism by interfering with epithelial and immune cells, generating an immune-inflammatory milieu that favors the progression of diabetes and its complication including diabetic retinopathy and nephropathy ([@bib0175]).

Gut microbiota dysbiosis has been also associated with a diversity of age-related cardiac and vascular disorders, including hypertension, heart failure, myocardial infarction, stroke and coronary artery disease, among others ([@bib0085]; [@bib0550]). Atherosclerosis, the background condition for several cardio and cerebrovascular disorders, is a chronic inflammatory disease that has been also associated with intestinal microbiota dysbiosis ([@bib0550]). Globally, patients with cardiovascular disease have been associated with major changes on bacterial populations, including an increased prevalence of Firmicutes and reduced of Bacterioidetes ([@bib0340]). In addition, experimental and clinical studies suggested that bacteria-derived endotoxins, namely LPS and PG, contributes to a chronic low-grade inflammation state, typical of atherosclerosis. Moreover, some populations of patients with increased risk for CVD presented seropositivity for some deleterious bacteria, namely Helicobacter pylori and Chlamydia pneumoniae ([@bib0330]). Overall, it is believed that bacteria-derived endotoxemia can contribute to CVD ([@bib0085]; [@bib0550]).

Further evidences reinforce the idea that disbyotic intestinal microbiota recruits additional harmful mechanisms that may contribute to atherogenesis pathogenesis. In particular, the formation of trimethylamine*-N-*oxide (TMAO), a pro-atherogenic product of the oxidation of trimethylamine, which is a metabolite originated by microbiota-mediated degradation of dietary free choline, phosphatidylcholine and carnitine metabolism ([@bib0365]; [@bib0670]). Systemic TMAO has been described as a potent promoter of atherosclerosis by reducing cholesterol absorption in enterocytes and bile acids synthesis in hepatocytes, together with enhanced cholesterol uptake by macrophages and subsequent formation of foam cells in atherosclerotic lesions ([@bib0365]). Several clinical studies showed a direct association between TMAO levels and the risk for CV events and mortality in distinct populations, including patients with age-related diseases, such as heart failure, coronary artery disease or acute coronary syndrome, which was recently reinforced by systemic reviews and meta-analysis ([@bib0275]; [@bib0570]).

Identical association of TMAO with CVD risk has been described in chronic kidney disease (CKD) patients, a disease with a marked inflammatory state and mortality mainly due to CV causes. In fact, increased TMAO levels were associated with augmented tubulointerstitial fibrosis, promotion of renal oxidative stress and inflammation in animal models ([@bib0645]), as well as with atherosclerotic disease and long-term mortality in kidney disease patients ([@bib0640]; [@bib0655]). In addition, several other metabolites formed upon degradation of food constituents by dysbiotic microbiota include uremic toxics, such as indoxyl sulfate (IS) and p-cresyl sulfate (PCS), end-products of amino acids (tryptophan, tyrosine and phenylalanine) fermentation, causing renal fibrosis and aggravation of kidney injury and dysfunction ([@bib0565]). Serum levels of IS and PCS are negatively correlated with renal function and gradually increases with kidney disease severity ([@bib0290]; [@bib0450]). Changes in the gut microbiota composition have been also reported in CKD patients, even at earlier disease stages ([@bib0045]). Inflammation and immune deregulation are important features of microbial dysbiosis in kidney disease ([@bib0485]). As a result of gut inflammation and of the leaky gut syndrome, LPS translocation stimulates immune system cells towards a massive production of pro-inflammatory cytokines which causes systemic inflammation ([@bib0020]; [@bib0535]). Collectively, evidences suggest a vicious cycle by which dysbiosis promotes chronic inflammation and contributes to kidney disease which, on the other hand, changes the gut milieu, thus modifying gut microbiome towards dysbiosis ([@bib0175]).

4. Crosstalk between gut microbiota dysbiosis, ACE2 and COVID-19 {#sec0045}
================================================================

An association between gut microbiota dysbiosis and the poor outcomes in elderly COVID-19 patients, particularly in those with pre-existing cardiovascular, cardiometabolic and cardiorenal diseases, could be hypothesized based on two aspects: i) the above-mentioned linkages between age-related gut microbiota dybiosis and cardiometabolic, cardiorenal and inflammatory disease; ii) gut microbiota dysbiosis, inaccurate local/distal host immunity towards viral infection and RAS deregulation driven by SARS-CoV-2-induced ACE2 shedding. In fact, strong epidemiological and biochemical data coming from the COVID-19 pandemics shows that elderly people with pre-existing cardiovascular, metabolic, renal, and lung diseases (including hypertension, coronary disease, diabetes, CKD and respiratory syndromes) are at higher risk of severe disease and mortality when infected ([@bib0115]; [@bib0240]; [@bib0435]; [@bib0490]; [@bib0545]; [@bib0715]). It has been reported that the frequency of cardio‐cerebrovascular diseases, hypertension and diabetes in infected patients who received care in the intensive care unit (ICU) could be three‐, two‐, and two folds higher, respectively, than counterparts receiving non‐ICU care ([@bib0435]). The percentage of persons hospitalized, who further need intensive care, increases with age, which is in line with the increased mortality rate in the elderly ([@bib0160]; [@bib0605]; [@bib0660]; [@bib0835]). As scrutinized in Section [3](#sec0030){ref-type="sec"}, immunosenescence and inflammaging phenotypes are regular key features of aforesaid age-related conditions. Notably, an exacerbated inflammatory phenotype could be strengthened by an impaired RAS signaling due to the loss of ACE2-protective functions upon SARS-CoV-2 infection, further contributing to the systemic "cytokine storm" and tissue injury ([@bib0400]; [@bib0690]; [@bib0710]) (see [Fig. 1](#fig0005){ref-type="fig"} , right). In further support of this thesis, LPS-induced acute lung injury in mice was able to reduce the expression of ACE2, exacerbating inflammatory injury and causing upregulation of other components of the RAS, namely renin, Ang II, ACE, and AT1 receptors ([@bib0770]). Interestingly, increased Ang II levels has been shown to directly impact gut microbial composition and metabolomics in a sex-specific manner ([@bib0105]).Fig. 1Putative association between ACE2 shedding after SARS-CoV-2 infection and the poor outcomes in elderly COVID-19 patients with pre-existing age-related cardiovascular, cardiometabolic and cardiorenal diseases. An imbalanced Ang II/Ang 1-7 ratio, due to the loss of ACE2 protective function, favors Ang II-AT1R signaling and subsequent vasoconstrictive, pro-hypertensive, pro-oxidant, pro-inflammatory and pro-fibrotic events (RAS-dependent pathway, right). Furthermore, ACE2 shedding may also dictate a dysbiotic gut condition (RAS-independent pathway, left). Briefly, loss of ACE2 integrity, a chaperone of intestinal B^0^AT1 carrier, may negatively impact neutral amino acids transport with subsequent mTOR-dependent AMPs disrupted synthesis, altered local immunity and gut microbiota dysbiosis. Concurrently, increased Ang II levels may also impair GM composition and function. Altered gut barrier permeability may add an extra-level of complexity to this scenario, allowing the translocation of local microbiota components to the bloodstream, including resident SARS-CoV-2 viral particles. Whether these events foster SARS-CoV-2 fecal-oral transmission deserves further studies. Nevertheless, such deleterious cascades may aggravate the pre-existing gut dysbiosis, systemic inflammation and impaired immune response in cardiovascular, cardiometabolic and cardiorenal patients, rendering them less suited to manage COVID-19 infection.Fig. 1

Besides, a RAS-independent cascade of events arising from reduced ACE2 function upon SARS-CoV-2 infection may also culminate in gut dysbiosis and increased susceptibility to inflammation, namely due to an impaired mTOR-mediated synthesis of AMPs ([@bib0525]) (see [Fig. 1](#fig0005){ref-type="fig"}, left). Experimentally, gain or loss of ACE2 function have been associated with amelioration and worsening of leaky gut conditions, respectively ([@bib0165]; [@bib0260]). Moreover, a RAS-independent ACE2 role on gut homeostasis (B°AT1/Trp transport) is concurrently reported. Gut microbiota dysbiosis, altered permeability of gut barrier and subsequent inefficient priming of local and systemic immunity are conditions that may be amplified due to the loss of ACE2 protective functions upon SARS-CoV-2 infection. Noteworthy, such events may be decisive in patients who previously display an immunosenescence, inflammaging and gut dysbiotic profile. Collectively, these observations stand for a putative involvement of gut dysbiosis within SARS-CoV-2 infection that may help to explain the poor outcomes of COVID-19 patients with pre-existing gut homeostasis derangements arising from age-related cardiovascular, renal and metabolic disorders. Accordingly, several recent evidences from COVID-19 patients highlight GI impairments (e.g diarrhea and other symptoms of GI discomfort) before the appearance of respiratory conditions ([@bib0370]), similarly to what was reported in previous coronavirus outbreaks ([@bib0420]). Notably, abdominal pain was more frequent in ICU admitted patients than in individuals who did not required ICU assistance ([@bib0700]). In previous CoVs outbreaks, the presence of viral RNA in feces was detected in a high percentage of patients with a more aggressive clinical course ([@bib0125]). Similarly, SARS-CoV-2 was detected in feces from COVID-19 patients and fecal-oral transmission has been also suggested ([@bib0745]). Collectively, the available evidences suggest that the GI tract of SARS-CoV-2 infected patients may act as a fertile ground for persistent viral replication, in line with previously reported for SARS-CoV. Strikingly, an elegant work of [@bib0790] corroborates this assumption by unequivocally demonstrating that SARS-CoV-2 is able to infect ACE2^+^ mature enterocytes in human small intestinal enteroids, a process mediated by TMPRSS2 and TMPRSS4 proteases. Yet, SARS-CoV-2 was rapidly inactivated by simulated human colonic fluid and infectious viruses were not recovered from the stool specimens of COVID-19 patients ([@bib0790]). Hence, future studies aimed to address SARS-CoV-2 fecal-oral transmission are still warranted. Nevertheless, enteric coronaviruses infection potentially evoke gut-blood barrier disruption, leading to systemic spread of bacteria, endotoxins, and microbial metabolites, which may further compromise the host's immune response to the infection and potentiate adverse outcomes, as detailed in Section [3](#sec0030){ref-type="sec"} ([@bib0420]; [@bib0775]). This storm may be coincident with disruption of the enteric ACE2 axis, cumulating in the dysfunction of several physiologic systems and, ultimately, septic shock ([@bib0115]; [@bib0240]). Coherently, a gut-lung axis has been proposed in the onset of pulmonary hypertension associated with a phenotype of gut dysbiosis and leaky gut linked with overactivation of the ACE/Ang II/AT1R axis due to ACE2 loss ([@bib0360]). Host enterocytes continuous viral production and ACE2 depletion, as well as GM dysbiosis, may perpetuate a disrupted gut-lung axis, as previously suggested for SARS-CoV ([@bib0420]).

As above mentioned, a dysbiotic condition, viewed by decreased microbial diversity and richness, as well as impaired Firmicutes to Bacteroidetes ratio, have been reported in elderly people and in age-related cardiovascular, metabolic, renal and pulmonary conditions. Herein, it is hypothesized that pre-existing disorders displaying altered gut microbiome may worsen SARS-CoV-2 infection due to ACE2 integrity/functionality loss. This assumption is strengthen by evidences coming from the ACE2-/y-Akita mice who display gut barrier disruption and exacerbated diabetes-induced dysbiosis ([@bib0165]). In this sense, SARS-CoV-2 infection may promote a significant reduction of enteric ACE2 expression and subsequent leakage of gut barrier, altered microbiota composition and metabolomic and aggravated endotoxemia/inflammation. This possibility is supported by recent data showing that some patients with COVID-19 presented intestinal microbial dysbiosis ([@bib0755]). Yet, it will be important to address in future studies the putative relationship with concomitant drugs intake that are able to modulate GM composition, such as antibiotics.

5. ACE2-based and microbiota-directed therapeutic opportunities for COVID-19 {#sec0050}
============================================================================

The discover that ACE2 is the receptor for SARS-CoV-2 entry in human cells ([@bib0285]) has raised the possibility of ACE2 and/or other RAS modulators to potentially treat COVID-19 ([@bib0810]). The precise implications (benefits vs risks) of use ACE inhibitors (ACEIs) and/or angiotensin receptor blockers (ARBs) on COVID-19 patients, namely in patients with hypertension ([@bib0675]), have been intensely discussed during the last months and several clinical trials are currently ongoing ([Table 1](#tbl0005){ref-type="table"} ). On one hand, these drugs could theoretically provide benefits viewed by the reduction of the extent of experimentally induced lung injury in animal models under RAS inhibition ([@bib0265]); on the other hand, these drugs have been suggested to upregulate ACE2 expression, which could eventually aggravate the outcomes by enhancing viral entry into the host cells ([@bib0555]). A study conducted with 18,472 patients tested for COVID-19 showed no association between ACEIs or ARBs use and COVID-19 test positivity ([@bib0495]). ACEIs/ARBs exposure was not associated with a higher risk of COVID-19 infection, neither with a higher risk of having severe infection or mortality, but was associated with a lower risk of mortality compared to those on non-ACEIs/ARBs antihypertensive drugs ([@bib0815]). The study further supported the current professional society's guidelines that discourage the discontinuation of ACEIs or ARBs in COVID-19 patients due to lower risk of mortality when therapy is maintained ([@bib0095]). Identical conclusions were obtained in other relevant studies and publications ([@bib0180]; [@bib0540]), including in a multinational open science cohort study involving 1.1 million antihypertensive users with distinct anti-hypertensive drug classes, which concluded the absence of clinically significant increased risk of COVID-19 diagnosis or hospitalization with ACEs or ARBs use and a recommendation for not discontinuation or change of treatment to avoid COVID-19 ([@bib0510]).Table 1Therapeutic opportunities under clinical evaluation for COVID-19 treatment targeting ACE2 or other RAS component (Clinicaltrial.gov).Table 1Therapeutic group(s)/ Drug(s)Patients' s conditionsStudy type and nr participants[\*](#tblfn0005){ref-type="table-fn"}CountryTrial ID and phase[\*\*](#tblfn0010){ref-type="table-fn"}ACEIs/\
ARBsCOVID-19 patients with HT\
(stage 1−2)Obs. / Prosp.\
10 participantsUkraineNCT04364984\
Phase: NAHospitalized COVID-19 patientsObs.\
2574 participantsSpainNCT04367883\
Phase: NAHospitalized COVID-19 patients\
with HTObs. / Retros.\
275 participantsChinaNCT04318301\
Phase: NAHospitalized COVID-19 patients treated with ACEIs or ARBsObs./Retros.\
5000 participantsItalyNCT04318418\
Phase: NACOVID-19 patientsObs./ Cross-Sec\
2000 participantsItaly\
(MC)NCT04331574\
Phase 4Hospitalized COVID-19 patients\
Current use of ACEIs or ARBsInterv. / Par. Ass.\
152 participantsUnited StatesNCT04338009\
Phase: NAHospitalized COVID-19 patients treated with ACEIs or ARBsInterv. / Par. Ass.\
554 participantsFranceNCT04329195\
Phase 3COVID-19 patients\
Current use of ACEIs or ARBs therapy for HT, DM, HF or CADInterv. / Par. Ass.\
208 participants25 locations\
(MC)NCT04353596\
Phase 4Hospitalized COVID-19 patients\
Current use of ACEIs or ARBsInterv. / Par. Ass.\
215 participantsDenmarkNCT04351581\
Phase: NACOVID-19 patients with HT, CAD, HF or DMObs. / Prosp.\
226 participantsSaudi ArabiaNCT04357535\
Phase: NAHospitalized COVID-19 patients\
Current use of ACEIs or ARBsInterv. / Par. Ass.\
500 participantsBrazilNCT04364893\
Phase: NAHospitalized COVID-19 patientsObs. / Retros\
700 participantsFranceNCT04374695\
Phase: NACOVID-19 patientsObs. / Prosp.\
504 participantsChina\
(MC)NCT04342702\
Phase: NASynthetic AMD vs ACEIs or ARBsCOVID-19 patients using AMD\
or ACEIs or ARBsObs. / Prosp. + Retros\
6000000 participantsFranceNCT04356417\
Phase: NAACEIsCOVID-19 patientsObs. / Retros\
60 participantsTurkeyNCT04379310\
Phase: NAACEI/\
Captopril or enalaprilCOVID-19 patientsInterv. / Par.Ass.\
60 participantsEgyptNCT04345406\
Phase 3ACEI/\
CaptoprilHospitalized COVID-19 patients with pneumoniaInterv. / Par. Ass.\
230 participantsFrance\
(MC)NCT04355429\
Phase 2ACEI/\
RamiprilHospitalized COVID-19 patientsInterv. / Par. Ass.\
560 participantsNot ProvidedNCT04366050\
Phase 2ARBsIUC hospitalized COVID-19 patientsObs. / Prosp.\
100 participantsFranceNCT04337190\
Phase: NACOVID-19 patientsInterv. / Par. Ass.\
605 participantsAustraliaNCT04394117\
Phase 4ARB/\
CandesartanCOVID-19 patients with\
HypertensionInterv. / Par. Ass.\
500 participantsAustria\
(MC)NCT04351724\
Phase 2/3ARB/\
LosartanCOVID-19 patients with HTInterv. / Par. Ass.\
200 participantsUnited States\
(MC)NCT04340557\
Phase 4COVID-19 patients with hypoxic respiratory failureInterv. / Sin.Group\
50 participantsUnited StatesNCT04335123\
Phase 1Hospitalized COVID-19 patientsInterv. / Par. Ass.\
4000 participantsUnited States\
(MC)NCT04328012\
Phase 2/3Hospitalized COVID-19 patients\
age ≥ 40 yearsInterv. / Fact. Ass.\
10000 participantsNigeria and Pakistan (MC)NCT04343001\
Phase 3COVID-19 patientsInterv. / Fact. Ass.\
500 participantsUnited StatesNCT04349410\
Phase 2/3COVID-19 patientsInterv. / Par. Ass.\
580 participantsUnited States (MC)NCT04311177\
Phase 2Hospitalized COVID-19 patientsInterv. / Par. Ass.\
200 participantsUnited States (MC)NCT04312009\
Phase 2COVID-19 patients with metastatic diseaseInterv. / Par. Ass.\
156 participantsBrazilNCT04447235\
Phase 2Hospitalized COVID-19 patientsInterv. / Par. Ass\
20 ParticipantsMexicoNCT04428268\
Phase 2ARB/\
TelmisartanHospitalized COVID-19 patientsInterv. / Par. Ass.\
1600 participantsFranceNCT04359953\
Phase 3COVID-19 patients with\
age ≥ 65 yearsInterv. / Par. Ass.\
845 participantsFrance\
(MC)NCT04356495\
Phase 3Hospitalized COVID-19 patientsInterv. / Par. Ass.\
40 participantsUnited StatesNCT04360551\
Phase 2COVID-19 patientsInterv. / Par. Ass.\
400 participantsArgentinaNCT04355936\
Phase 2ARB/\
ValsartanHospitalized COVID-19 patientsInterv. / Par. Ass.\
651 participantsNetherlandsNCT04335786\
Phase 4Angiotensin 1−7IUC hospitalized COVID-19 patientsInterv. / Par. Ass.\
60 participantsNot ProvidedNCT04332666\
Phase 2/3Hospitalized COVID-19 patientsInterv. / Par. Ass.\
100 participantsNo ProvidedNCT04401423\
Phase 2Isotretinoin /\
Down-regulator of\
ACE2 receptorsCOVID-19 patientsInterv. / Par. Ass.\
300 participantsNot ProvidedNCT04361422\
Phase 3IsotretinoinIUC hospitalized COVID-19 patients with SRFInterv. / Par. Ass.\
1000 participantsEgyptNCT04353180\
Phase 2/3Isotretinoin + TamoxifenIUC hospitalized COVID-19 patients with SRFInterv. / Seq. Ass.\
160 participantsNot ProvidedNCT04389580\
Phase 2TMPRSS2 Inhibitor/ Nafamostat MesilateHospitalized COVID-19 patientsInterv. / Par.Ass.\
256 participantsNot ProvidedNCT04352400\
Phase 2/3TMPRSS2 Inhibitor/\
Camostat MesilateHospitalized COVID-19 patientsInterv. / Par.Ass.\
580 participantsDenmark\
(MC)NCT04321096\
Phase 1/2TMPRSS2 Inhibitor/ BromhexineHospitalized COVID-19 patientsInterv. / Par.Ass.\
90 participantsNot ProvidedNCT04355026\
Phase 4rhACE2/\
APN01Hospitalized COVID-19 patientsInterv. / Par.Ass.\
200 participantsAustria, Denmark and Germany (MC)NCT04335136\
Phase 2rbACE2COVID-19 patientsInterv. / Par.Ass.\
24 participantsNot ProvidedNCT04375046\
Phase 1rbACE2 + IsotretinoinCOVID-19 patientsInterv. / Par.Ass.\
24 participantsNot ProvidedNCT04382950\
Phase 1Microparticles with ACE2COVID-19 patientsObs. / Prosp.\
175 participantsNot ProvidedNCT04448743\
Phase: NA[^1][^2][^3]

Other therapeutic approaches may rely on Ang 1--7 receptors agonists or recombinant human ACE2 (rhACE2) as replacement strategies, an attempt to maintain an adequate degree of RAS counter-regulation via the ACE2/Ang1--7/MasR axis that may be particularly useful in patients with pre-existing cardiovascular/metabolic/renal pathologies. Beneficial effects were observed in CVD and lung disease upon rhACE2 or AVE 0991 administration, an agonist of Ang 1--7 receptors ([@bib0520]). In fact, AVE 0991 showed cardiac, renal and pulmonary beneficial effects, while rhACE2 treatment was able to ameliorate the symptoms of CVD, kidney injury and acute lung injury in preclinical research ([@bib0315]; [@bib0335]; [@bib0830]). Regarding acute lung injury of distinct etiologies, including the one induced by SARS-CoV, rhACE2 also promoted beneficial effects ([@bib0315]; [@bib0335]; [@bib0385]). Due to the ability to scavenge circulating viral particles along with the putative beneficial effect arising from RAS counter-regulation, rhACE2 has been viewed as a promising therapeutic strategy for COVID-19 patients and is currently under clinical trials ([Table 1](#tbl0005){ref-type="table"}).

It is worth to mention that previous studies with the rhACE2 APN01 (GSK2586881) have shown a safe profile both in healthy volunteers as well as in a small cohort of patients with acute respiratory distress syndrome ([@bib0255]; [@bib0355]; [@bib0795]). Overall, the supply of ACE2 soluble forms might exert a dual beneficial function within SARS-CoV-2 infection, by slowing the virus entry into host cells while ensuring the putative maintenance of ACE2 contra-regulatory functions on RAS, assisting in the protection from lung injury.

Another possibility to halt SARS-CoV-2 entry into host cells that deserves further attention is the inhibition of TMPRSS2 activity ([@bib0280]; [@bib0325]). Camostat mesylate, a TMPRSS2 inhibitor, was tested in the past within SARS and MERS infections and has been reported as a possible effective option. In addition, blocking ACE2 with antibodies or small molecules/peptides can also be a promising strategy that deserves further research.

The possibility of consistent intestinal microbial dysbiosis in patients with COVID-19 is under evaluation (see [Table 2](#tbl0010){ref-type="table"} of ongoing clinical trials) and was already suggested by some studies (see Section [3.1](#sec0035){ref-type="sec"}). In this sense, therapeutic nutritional measures to equilibrate gastrointestinal function and microbiota could be important, including the use of prebiotics or probiotics in order to reduce the risk of secondary infection due to bacterial translocation. In addition, the use of bioengineered probiotic species has been envisaged as live vectors to deliver pharmacological agents. This approach was used with success in mice with diabetic retinopathy treated with the recombinant *Lactobacillus paracasei* expressing the secreted ACE2 in fusion with the non-toxic subunit B of cholera toxin (acts as a carrier to facilitate transmucosal transport) ([@bib0680]), and could be replicated using COVID-19 infection as the target conditions.Table 2Clinical trials with COVID-19 patients for the study of gut microbiota (Clinicaltrial.gov).Table 2Intervention/Main aimsPatients' s conditionsStudy type and nr participants[\*](#tblfn0015){ref-type="table-fn"}CountryTrial ID and phase[\*\*](#tblfn0020){ref-type="table-fn"}Changes in fecal microbiota compositionHospitalized COVID-19 patientsObs. / Prosp. 170 participantsHong KongNCT04325919\
Phase: NAChanges in respiratory and fecal microbiota compositionCOVID-19 patients admitted to the ICUObs. / Prosp.\
30 participantsNot ProvidedNCT04359706\
Phase: NAChanges in fecal microbiota compositionCOVID-19 patients:\
self-isolated at home; in an isolated hospital and in the ICU of the hospitalObs. / Prosp.\
60 participantsPortugal\
(MC)NCT04355741\
Phase: NAProbiotic supplementation - SivoMixxHospitalized COVID-19 patientsInterv. / Par. Ass.\
152 participantsItalyNCT04366089\
Phase 2Changes in fecal microbiota compositionHospitalized COVID-19 patientsObs. / Prosp.\
2000 participantsFranceNCT04332016\
Phase: NA0Correlation of immune profiling with microbiome analysisHospitalized COVID-19 patientsObs. / Prosp.\
100 participantsNot providedNCT04327570\
Phase: NAProbiotic supplementationHospitalized COVID-19 patientsInterv. / Par. Ass.\
40 participantsSpainNCT04390477\
Phase: NAProbiotic supplementation -- SivoMixx + AzithromycinHospitalized COVID-19 patientsObs. / Retros.\
70 participantsItalyNCT04368351\
Phase: NACorrelation of feces microbiome and clinical outcome for COVID-19COVID-19 patientsObs. / Prosp.\
150 participantsNot providedNCT04359459\
Phase: NACorrelation between oral microbiome and COVID-19 infection statusAsymptomatic COVID-19 patientsObs. / Prosp.\
500 participantsNot providedNCT04345510\
Phase: NASupplementation with natural polyphenols-TanninsHospitalized COVID-19 patientsInterv. / Par. Ass.\
140 participantsNot providedNCT04403646\
Phase: NAChanges in fecal microbiota compositionCOVID-19 patientsObs.\
250 participantsUnited StatesNCT04359836\
Phase: NAProbiotic supplementation - Omnibiotic ® AADCOVID-19 patients with pre-existing diarrhoeaInterv. / Par. Ass.\
108 participantsAustriaNCT04420676\
Phase: NACorrelation of gut microbiome to diseaseCOVID-19 patientsObs.\
250 participantsUnited StatesNCT04359836\
Phase: NA[^4][^5][^6]

Among the range of therapeutic options that have been tested to treat patients with COVID-19, there are some that have been shown the ability to modulate the intestinal microbiota. Concerning drugs, the anti-malarial drugs chloroquine and hydroxychloroquine, the lipid-lowering drugs statins, together with immunomodulatory and anti-inflammatory agents such as some interferons and corticosteroids (including dexamethasone), have been shown to interfere with GM ([@bib0025]; [@bib0295]; [@bib0665]; [@bib0825]). Regarding nutraceutical interventions, several options able to modulate GM have been recently suggested as potentially useful in combating COVID-19 or its associated symptoms ([@bib0010]; [@bib0155]; [@bib0785]); among them, vitamins, selenium and zinc, flavonoids, omega‐3 polyunsaturated fatty acids and a panoply of herbs/compounds from traditional chinese medicine ([@bib0150]; [@bib0170]; [@bib0395]; [@bib0635]; [@bib0765]). Although the effects described for nutraceutical options are generically symbiotic, the same is not always true for drugs, some of which not only affect the microbiota composition and function but can also be affected by it, in interactions that can be symbiotic or dysbiotic. However, the effects on gut microbiota of these approaches have been mainly described in other pathological conditions (experimental or clinical), and there is still no relevant information on their influence in patients with COVID-19, deserving further elucidation.

Finally, a warning note related to this disease and intestinal microbiota dysbiosis. The existence of gastrointestinal symptoms in some patients affected by COVID-19, and the detection of SARS-CoV-2 in feces, which can persist positive even after the virus is eliminated from the respiratory tract, suggest the possibility of a fecal--oral route of transmission ([@bib0750]). In this sense, an international group of experts in fecal microbiota transplantation and stool banking have suggested a rapid revision of recommendations in order to avoid contamination from donors, who should be carefully screened before donating ([@bib0305]).

6. Conclusions and future challenges {#sec0055}
====================================

ACE2 has a trilogy of roles with clear relevance in COVID-19 pathophysiology with expected impact on both its outcome and management/treatment. ACE2 is the SARS-CoV-2 receptor in humans, which is cleaved by transmembrane proteases (e.g. TMPRSS2) upon viral infection. ACE2 signaling on MasR receptor displays an important RAS counter-regulatory activity of the pro-vasoconstrictor, pro-fibrotic, pro-oxidant and pro-inflammatory activities of Ang II via AT1R. When "neutralized" after viral infection, ACE2-protective effects on cardiovascular, renal and pulmonary systems are weakened, which is particularly critical in elderly individuals with aforesaid pre-existing age-related conditions, which have been described as the most severely affected upon SARS-CoV-2 infection. In addition, GI symptoms have also been described in a considerable percentage of infected patients, suggesting a gastrointestinal-enteric pathway. Gut microbiota dysbiosis and impaired intestinal-blood barrier (leaky gut) have been associated with the development of atherosclerosis and increased risk of CVD and mortality in cardiovascular patients, as well as in individuals with obesity, diabetes or chronic renal disease. Interestingly, ACE2 plays a major role in amino acid transport in the intestinal epithelium, a mechanism that is linked with the production of antimicrobial peptides, thus interfering with gut microflora equilibrium. In conditions of ACE2 shedding, as occurs after viral S-protein priming, gut microbiota dysbiosis might be favored, thus further contributing and eventually explaining the poor outcomes in elderly COVID-19 patients, especially in those with pre-existing age-related cardiovascular, metabolic and renal comorbidities, which present higher frequency of ICU admission (disease severity) and increased mortality rate.

Considering the crucial role of ACE2 on COVID-19 and the potential impact on the worsened outcome of some patients, several therapeutic approaches have been tested, which are mainly based on the following strategies: - soluble form of ACE2, such as rhACE2; - ACE2 blockers (anti-antibodies or small molecules/peptides); - TMPRSS2 inhibitors; - Ang 1--7 receptor agonists; - ACE inhibitors and/or ARBs. Some of these pharmacological strategies appear to show promising results and some of them are currently moving to clinical trials. In addition, manage the patients' intestinal leakage and microbiota dysbiosis may be also relevant, namely using nutritional measures with prebiotic and/or probiotic activity, including bioengineered probiotic strategies able to deliver pharmacological agents.

The coming times will certainly uncover new data that will help to clarify this issue and, hopefully, effective solutions to solve this pandemic or other similar scenarios that the future might bring.
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[^1]: ACE2, angiotensin converting enzyme 2; ACEIs, angiotensin-converting enzyme inhibitors; AMD, anti-malarial drugs; ARBs, angiotensin II receptor blockers; CAD, coronary artery disease; COVID-19, Coronavirus disease; Cross-Sec, Cross-Sectional; DM, diabetes mellitus; Fact. Ass., Factorial Assignment; HF, heart failure; HT, Hypertension; ICU, intensive care unit; Interv., interventional; MC, Multicentre; NA, not applicable; Obs., observational; Par. Ass., parallel assignment; Prosp., prospective; RAS, renin-angiotensin system; rbACE2, recombinant bacterial angiotensin-converting enzyme 2; Retros., retrospective study; rhACE2, recombinant human angiotensin-converting enzyme 2; SRF, severe respiratory failure; Seq. Ass., Sequential Assignment; Sin. Group., Single group assignment; TMPRSS2, Transmembrane Serine Protease 2.
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[^3]: FDA definitions of clinical trial phases.

[^4]: COVID-19, Coronavirus disease; ICU, intensive care unit; Interv., interventional; MC, multicentre study; NA, not applicable; Obs., observational; Par. Ass., parallel assignment; Prosp., prospective.
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